DAIC

MARCH 28, 2025

CCTA offers a non-invasive, cost-effective, and highly sensitive method for diagnosing coronary artery disease (CAD), making it a valuable tool for clinicians. vii Similarly, recent increases in Medicare reimbursement rates for CCTA are a positive step towards making this technology more accessible. June 11, 2021.

Technology 59

Technology Coronary Artery Disease Atrial Fibrillation Medicare 59

DAIC

OCTOBER 16, 2024

The SCCT HPPC offers tools for administrators to navigate the complex landscape of insurance plans, billing and reimbursement on SCCT website, scct.org. Novitas Solutions and First Coast Service Options, Inc. FCSO ) continue to consider coverage for AI-CPA on a case-by-case basis.

CMS 52

CMS Medicare Plaque Chest Pain 52

DAIC

JULY 17, 2024

The PRECISE clinical trial data, originally presented in late 2022, confirmed CTA + FFR CT increases diagnostic accuracy, reduces unnecessary testing and offers higher confidence in identifying patients needing treatment versus traditional testing (stress nuclear, stress echo, and invasive coronary angiography).

Coronary Artery Disease 105

Coronary Artery Disease Chest Pain Reimbursement Plaque 105

CardiacWire

JANUARY 10, 2025

A recent study out of UCLA added to the growing body of evidence supporting AI-assisted CCTA as an alternative to SPECT for diagnosing obstructive coronary artery disease, especially in women. SPECT continues to be a first-line test to diagnose coronary ischemia, often instead of or before invasive coronary angiography.

Coronary Artery Disease 59

Coronary Artery Disease Ischemia Chest Pain Reimbursement 59